Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 5/20 | 0.58 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 4/20 | 0.35 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15243711 | 1.00 | CREBBP (0.58) | CREBBPBRPF1GSK3BPOLBTSHR | |
| SCHEMBL30858481 | 0.81 | CREBBP (0.59) | CREBBPBRPF1GSK3BPOLBTSHR | |
| SCHEMBL24157395 | 0.78 | BRPF1 (0.47) | CREBBPBRPF1GSK3BPOLBTSHR | |
| SCHEMBL30212596 | 0.78 | BRPF1 (0.47) | CREBBPBRPF1GSK3BPOLBTSHR | |
| SCHEMBL14765075 | 0.77 | CREBBP (0.54) | CREBBPBRPF1GSK3BTSHRCA12 | |
| SCHEMBL24157211 | 0.77 | BRPF1 (0.46) | CREBBPBRPF1GSK3BPOLBTSHR | |
| SCHEMBL30212561 | 0.77 | BRPF1 (0.46) | CREBBPBRPF1GSK3BPOLBTSHR | |
| SCHEMBL24156584 | 0.77 | BRPF1 (0.46) | CREBBPBRPF1GSK3BPOLBTSHR | |
| SCHEMBL30418429 | 0.76 | DYRK2 (0.37) | CREBBPBRPF1PDE7APBRM1CA12 | |
| SCHEMBL17928722 | 0.76 | CREBBP (0.53) | CREBBPBRPF1GSK3BPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409536-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2024-12-12 | — | — | US | disclosed |
| EP-4395891-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-118234724-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2023034811-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023034811-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| US-9394297-B2 | Amides as pim inhibitors | AMGEN INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2015-11-19 | — | — | US | disclosed |
| WO-2013034758-A1 | SUBSTITUTED TRIAZOLOPYRAZINES AND USES THEREOF | H. LUNDBECK A/S (DK) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409536-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | CREBBP 702/4885BRPF1 1749/4885GSK3B 2958/4885 |
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | PIM1, PIM3, PIM2 | CREBBP 65/4885BRPF1 3094/4885GSK3B 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.